Ryman Healthcare Limited
Ryman Healthcare Limited (RHCGF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rhcgf · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Ryman Healthcare Limited (RHCGF) measures how much investors pay for each dollar of the company's trailing earnings. RHCGF's current PE ratio of N/A is calculated by dividing its stock price of $1.41 by its TTM earnings per share of -$0.17.
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 18 fiscal years · Front-end computedMinQ1 · 25%13.0x
MedianQ3 · 75%810.0x
Max
At N/A, RHCGF's current P/E is lower than in 0% of its annual fiscal year readings over the past 18 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Care Facilities · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Ryman Healthcare LimitedYou RHCGF | $1.4B | N/A | — | -$0.17 |
 Ansell Limited ANSLY | $2.8B | 28.42x | +29.4% | $2.80 |
 Bumrungrad Hospital Public Company Limited BUGDF | $3.8B | 18.03x | -17.9% | $9.44 |
 Galapagos N.V. GLPGF | $1.9B | 5.47x | -75.1% | $4.87 |
 Jinxin Fertility Group Limited JXFGF | $2.6B | N/A | — | -$0.35 |
 MediPal Holdings Corporation MAHLY | $4.0B | 12.80x | -41.7% | $219.14 |
 Medicover AB (publ) MCVEF | $2.7B | 45.10x | +105.3% | $0.51 |
Industry Average 5 peers with valid PE | — | 21.96x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | — | $-0.17 | — | |
2025-03-31 FY2025 | — | $-0.62 | — | |
2024-03-31 FY2024 | 810.00x | $0.01 | +7343.8% | |
2023-03-31 FY2023 | 10.88x | $0.50 | +53.3% | |
2022-03-31 FY2022 | 7.10x | $1.31 | -64.2% | |
2021-03-31 FY2021 | 19.80x | $0.80 | -43.2% | |
2020-03-31 FY2020 | 34.88x | $0.50 | +111.6% | |
2019-03-31 FY2019 | 16.48x | $0.65 | +15.2% | |
2018-03-31 FY2018 | 14.31x | $0.78 | +22.1% | |
2017-03-31 FY2017 | 11.72x | $0.71 | +3.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Ryman Healthcare Limited (RHCGF) measures how much investors pay for each dollar of the company's trailing earnings. RHCGF's current PE ratio of N/A is calculated by dividing its stock price of $1.41 by its TTM earnings per share of -$0.17.
Frequently asked questions
RHCGF pe ratio · 6 questionsRHCGF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.41 and TTM EPS of -$0.17. Data sourced from Financial Modeling Prep via RHCGF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Ryman Healthcare Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09